ArticleInternational journal of clinical and experimental pathology2017
Targeting survivin suppresses proliferation and invasion of retinoblastoma cells
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- A decision process for drug discovery in retinoblastoma.Investigational new drugs · 2021Article
- Autophagy-related gene 7 deficiency caused by miR-154-5p overexpression suppresses the cell viability and tumorigenesis of retinoblastoma by increasing cell apoptosis.Annals of translational medicine · 2020Article
Corrections and comments
- Retraction · 2021-01-01Lack of Approval from Author · Results Not Reproducible ·
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survivin is a member of the inhibitor of apoptosis (IAP) family and has multifunctional properties that include aspects of proliferation, invasion and cell survival control. Survivin is a promising candidate for targeted cancer therapy as its expression is associated with poor clinical outcome and more aggressive clinicopathologic features. Retinoblastoma (RB) is a highly invasive malignant tumor that often invades the brain and metastasizes to distal organs through the blood stream. However, expression of survivin in RB has not been previously characterized. In addition, whether survivin could be used for targeted RB therapy is not clear. In the present study, we demonstrated that RB tumors with invasion showed significantly higher expression of survivin compared to tumors without invasion (
Indexed as
Identifiers
31966807PMC6965960W3010624073What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.